8-K: ResMed Q3 2026 Earnings: 11% Revenue Growth

ResMed reported strong third-quarter fiscal 2026 results with 11% revenue growth and significant margin expansion.

Summary

• Revenue reached $1.43 billion, an 11% increase year-over-year.
• GAAP diluted earnings per share (EPS) were $2.74, while non-GAAP diluted EPS reached $2.86.
• Non-GAAP gross margin expanded by 290 basis points to 62.8%.
• Operating cash flow for the quarter was $554 million.
• The company returned $262 million to shareholders through dividends and share repurchases.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, characterized by double-digit revenue growth, significant margin expansion, and strong cash flow generation.

Positives

• 11% reported revenue growth (8% on a constant currency basis).
• Non-GAAP gross margin expansion of 290 basis points to 62.8%.
• Strong operating cash flow of $554 million.
• Non-GAAP net income increased by 20% to $417 million.
• Consistent demand for sleep devices, masks, and accessories.

Negatives

• Selling, general, and administrative (SG&A) expenses increased by 16% on a GAAP basis.
• Recorded $5.9 million in acquisition and portfolio review-related expenses.
• Short-term debt increased to $259.9 million from $9.9 million at the end of the previous fiscal year.

Risks

• Foreign currency fluctuations impacting reported revenue and margins.
• Potential for increased costs related to future acquisitions or strategic portfolio reviews.
• Regulatory developments and macroeconomic conditions affecting global supply chains.
• Risks associated with the integration of acquired businesses like VirtuOx.

Future Outlook

Management remains focused on expanding global access to care, scaling digital health capabilities, and delivering strong, profitable growth for the remainder of fiscal year 2026. A new distribution center in Greenwood, Indiana, is scheduled to begin operations in 2027.

Management Comments

• Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy.
• These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of sleep health, breathing health, and healthcare in the home.

Industry Context

StockSavvy.ai notes that ResMed continues to outperform in the sleep apnea and home healthcare device market, maintaining strong margins despite inflationary pressures. The company's focus on digital health and AI-powered solutions aligns with broader industry trends toward remote patient monitoring and home-based care.

Comparison to Industry Standards

• ResMed's 62.8% non-GAAP gross margin remains at the high end of the medical device industry, outperforming many peers in the respiratory space.
• The company's consistent dividend and share repurchase program demonstrate a capital allocation strategy similar to mature, large-cap healthcare technology firms.

Corporate Governance

Stakeholder Impact

• Shareholders benefit from the $0.60 per share dividend and ongoing share repurchases.
• Patients and providers will benefit from expanded distribution capacity in North America starting in 2027.

Next Steps

• Dividend payment on June 18, 2026.
• Continued integration of VirtuOx acquisition.
• Development of the new distribution center in Greenwood, Indiana, for 2027 launch.

Key Dates

Recommendation

The company demonstrates strong operational efficiency, consistent growth in core markets, and a disciplined capital allocation strategy, making it a solid choice for long-term investors.

Keywords

ResMed, sleep health, medical devices, digital health, earnings report, RMD, healthcare technology